Found 131 clinical trials
-
Phase 3 trial
-
Accepting pediatric ages
-
Currently Recruiting
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without the Poly ADP-ribose Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic or Locally Advanced Unresectable Breast Cancer Gene (BRCA)-Associated Breast Cancer
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without the Poly ADP-ribose Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Human Epidermal Growth Factor
- 74 views
- 08 Nov, 2020
- 1 location
-
Multi-country trial
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low Hormone Receptor Positive Metastatic Breast Cancer
This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low
- 35 views
- 17 Jan, 2021
- 183 locations
-
Multi-country trial
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer
therapy and will explore clinical benefit according to human epidermal growth factor receptor 3 (HER3) tumor expression level in otherwise refractory tumors.
- 0 views
- 25 Jan, 2021
- 38 locations
-
Multi-country trial
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Pulmonary/Respiratory Diseases
-
Currently Recruiting
A Trial of TAK-788 (AP32788) in Non-small Cell Lung Cancer (NSCLC)
and its active metabolites, anti-tumor activity of TAK-788 in participants with NSCLC with epidermal growth factor receptor (EGFR) or human epidermal growth factor 2 (HER2) mutations, explore
- 0 views
- 31 Dec, 2020
- 98 locations
-
Multi-country trial
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.
- 50 views
- 28 Dec, 2020
- 199 locations
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
1000s of participants
-
An interventional trial
-
For females only
-
Currently Recruiting
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer
Given the uncertain benefit in efficacy of adding CDK 4/6 to first rather than second line endocrine treatment, the aim of this project is to evaluate whether the sequence of an aromatase inhibitor plus CDK 4/6 in first line followed by fulvestrant in second line is superior to the sequence …
- 71 views
- 23 Jan, 2021
- 72 locations
-
Phase 4 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For females only
-
Currently Recruiting
Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy
This is a phase IV, single-center, prospective, open-label, randomized,controlled study
- 0 views
- 04 Nov, 2020
- 1 location
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For females only
-
Currently Recruiting
Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer
-N3), metastasis 0 (cM0), hormone receptor positive (HR+) (estrogen-receptor-positive (ER+) and/or progesterone-receptor-positive (PR+) human epidermal growth factor receptor 2 (HER2) negative or
- 0 views
- 24 Jan, 2021
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For females only
-
Oncology
-
Currently Recruiting
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2
- 0 views
- 24 Jan, 2021
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
The purpose of this study is to assess the safety and efficacy of alpelisib plus fulvestrant in men and postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor 2
- 0 views
- 24 Dec, 2020
- 4 locations